Brett Kaplan is a Managing Director in the firm’s corporate advisory business.
Mr. Kaplan advised Bristol-Myers on its acquisition of Amylin, Terumo on its acquisition of CaridianBCT, and Fenwal on its sale to Fresenius SE, and Axovant and Novocure on their IPO.
Prior to joining Evercore, Mr. Kaplan was a Large Cap Pharmaceuticals equity research analyst at Cowen and Company. Previously, he was a Director in the corporate development group of Cubist Pharmaceuticals and a Manager in business and clinical development with Biopure Corporation. Mr. Kaplan also spent time at Eli Lilly, South Africa as a Manager of business development and corporate strategy.
Mr. Kaplan received an M.B.A. and MBBCh from the University of the Witwatersrand, South Africa.